Why Is Omnipod Insulin Device Maker Insulet Stock Jumping Today?
Why Is Omnipod Insulin Device Maker Insulet Stock Jumping Today?
Insulet Corporation (NASDAQ:PODD) shares are trading higher after the company reported preliminary second-quarter results.
Insulet Corporation（纳斯达克股票代码：PODD）公布第二季度初步业绩后，该公司股价走高。
The company reported preliminary revenue of $488 million for the second quarter of 2024, marking a 23% increase from the $397 million reported in the previous year. The figure outpaces the street view of $460.27 million.
该公司报告称，2024年第二季度的初步收入为4.88亿美元，较去年公布的3.97亿美元增长了23％。这个数字超过了4.6027亿美元的街景。
"Second quarter revenue exceeded our expectations across the board as a result of strong demand for Omnipod 5, resulting in robust revenue growth and sequential increases in new customer starts in both the U.S. and international markets," said Jim Hollingshead, President and Chief Executive Officer.
总裁兼首席执行官吉姆·霍林斯黑德表示：“由于对Omnipod 5的强劲需求，第二季度的收入全面超出了我们的预期，这导致了强劲的收入增长以及美国和国际市场新客户数量的连续增长。”
This outperformance exceeds the guidance range of 15% to 18% in constant currency, driven by strong revenue growth across all product lines.
在所有产品线的强劲收入增长的推动下，这种跑赢大盘的表现超过了按固定汇率计算的15％至18％的指导区间。
Also Read: Walgreens Mulls Bond Sale As JPMorgan Gauges Investor Appetite: Report
另请阅读：摩根大通衡量投资者胃口之际，沃尔格林考虑出售债券：报告
Total Omnipod revenue reached $480 million, reflecting a 26% increase. In the U.S., Omnipod revenue was $352 million, up 27%.
Omnipod的总收入达到4.8亿美元，增长了26％。在美国，Omnipod收入为3.52亿美元，增长27％。
Internationally, Omnipod revenue totaled $128 million, marking a 23% increase, or 24% when adjusted for constant currency.
在国际上，Omnipod总收入为1.28亿美元，增长了23％，按固定货币调整后增长了24％。
Outlook Raised: When it releases its full financial results on August 8, 2024, the company expects to raise its full-year 2024 total Omnipod revenue outlook to 18% to 21% (previously 15% to 19%).
展望提高：该公司预计将在2024年8月8日发布完整财务业绩时将其2024年全年Omnipod总收入展望提高至18％至21％（此前为15％至19％）。
Yesterday, Insulet's peer DexCom, Inc. (NASDAQ:DXCM) reported mixed second-quarter financial results and weak forward guidance.
昨天，Insulet的同行德克斯康公司（纳斯达克股票代码：DXCM）公布的第二季度财务业绩喜忧参半，前瞻性指导疲软。
Price Action: PODD shares are trading higher by 8.45% to $207.00 premarket at last check Friday.
价格走势：周五最后一次检查时，PODD股价盘前交易价格上涨8.45％，至207.00美元。
Photo via Company
照片来自公司
- Bill Ackman's US Fund IPO Target Slashed By 90% As Pershing Square 'Specifically Disclaims' CEO's Comments
- 由于潘兴广场 “特别免责声明” 首席执行官的言论，比尔·阿克曼的美国基金首次公开募股目标下调了90％